Assertio Therapeutics Inc (ASRT) - Total Liabilities
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has total liabilities worth $135.67 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ASRT shareholders equity momentum to track the company's year-over-year net asset growth rate.
Assertio Therapeutics Inc - Total Liabilities Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Assertio Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Assertio Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Assertio Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fursys
KO:016800
|
Korea | ₩77.20 Billion |
|
AMA Group Ltd
AU:AMA
|
Australia | AU$649.09 Million |
|
Orogen Royalties Inc
V:OGN
|
Canada | CA$1.51 Million |
|
Jarllytec Co Ltd
TWO:3548
|
Taiwan | NT$5.50 Billion |
|
Theta Gold Mines Ltd
AU:TGM
|
Australia | AU$24.97 Million |
|
Leclanche SA
SW:LECN
|
Switzerland | CHF166.92 Million |
|
Gala Precision Engineering
NSE:GALAPREC
|
India | Rs719.30 Million |
|
USBC, Inc.
NYSE MKT:USBC
|
USA | $12.14 Million |
Liability Composition Analysis (1996–2025)
This chart breaks down Assertio Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Assertio Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Assertio Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual total liabilities of Assertio Therapeutics Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $173.02 Million | +5.72% |
| 2024-12-31 | $163.65 Million | +10.27% |
| 2023-12-31 | $148.42 Million | -21.13% |
| 2022-12-31 | $188.19 Million | -16.04% |
| 2021-12-31 | $224.13 Million | -9.54% |
| 2020-12-31 | $247.76 Million | -47.20% |
| 2019-12-31 | $469.21 Million | -34.15% |
| 2018-12-31 | $712.53 Million | -18.02% |
| 2017-12-31 | $869.11 Million | -10.82% |
| 2016-12-31 | $974.55 Million | -7.04% |
| 2015-12-31 | $1.05 Billion | +202.46% |
| 2014-12-31 | $346.62 Million | -6.63% |
| 2013-12-31 | $371.24 Million | +543.20% |
| 2012-12-31 | $57.72 Million | -1.26% |
| 2011-12-31 | $58.45 Million | -8.56% |
| 2010-12-31 | $63.92 Million | -15.73% |
| 2009-12-31 | $75.86 Million | +22.48% |
| 2008-12-31 | $61.93 Million | +76.32% |
| 2007-12-31 | $35.12 Million | -56.04% |
| 2006-12-31 | $79.91 Million | +34.03% |
| 2005-12-31 | $59.62 Million | +312.14% |
| 2004-12-31 | $14.47 Million | +10.28% |
| 2003-12-31 | $13.12 Million | -55.68% |
| 2002-12-31 | $29.59 Million | +189.45% |
| 2001-12-31 | $10.22 Million | +146.58% |
| 2000-12-31 | $4.15 Million | -68.63% |
| 1999-12-31 | $13.22 Million | +1101.49% |
| 1998-12-31 | $1.10 Million | +120.00% |
| 1997-12-31 | $500.00K | -28.57% |
| 1996-12-31 | $700.00K | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more